☆ 4.6 Review

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study

CANCERS (2022)

Related references

Note: Only part of the references are listed.

Review Urology & Nephrology

Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials

Alessandro Rizzo et al.

Summary: This study conducted a meta-analysis to explore the predictive value of immune checkpoint inhibitors (ICI) plus tyrosine kinase inhibitors (TKI) in the treatment of metastatic renal cell carcinoma (mRCC) patients. The results showed that the combination therapy had significant survival benefits in different clinicopathological subgroups.

EUROPEAN UROLOGY FOCUS (2022)

Add to Collection

Review Oncology

The immune response to major gastrointestinal cancer surgery and potential implications for adjuvant immunotherapy

Noel E. Donlon et al.

Summary: The perioperative period is a critical time for tumor micrometastasis progression, and the timing of introducing cancer therapies is crucial. Through exploring perioperative immune events at a cellular level and reviewing clinical trials, this study extrapolates the effects of oncological surgery on the perioperative immune milieu. The review focuses on perioperative immunosuppression, identifies potential modifiable factors, and discusses the combination of immunotherapy and major oncological gastrointestinal surgery.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

Add to Collection

Review Oncology

Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy

Gary Ng et al.

Summary: Immunotherapy and targeted therapy have improved outcomes for melanoma patients, but there is a need for further research to guide clinical decisions regarding relapse.

CURRENT ONCOLOGY REPORTS (2022)

Add to Collection

Article

Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?

Christopher D. Lao et al.

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting (2022)

Add to Collection

Article Urology & Nephrology

Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma

Alberto Martini et al.

Summary: The treatment landscape for renal cell carcinoma is rapidly evolving, with nine studies currently evaluating the role of immunotherapy in the neoadjuvant setting and four studies in the adjuvant setting.

WORLD JOURNAL OF UROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Article Oncology

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Joaquim Bellmunt et al.

Summary: IMvigor010 is the largest adjuvant study evaluating a checkpoint inhibitor in muscle-invasive urothelial carcinoma. The trial did not show improved disease-free survival with atezolizumab compared to observation. Atezolizumab was generally well tolerated, but higher rates of adverse events leading to discontinuation were reported compared to previous studies on metastatic urothelial carcinoma.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander M. M. Eggermont et al.

Summary: The study demonstrated that adjuvant pembrolizumab therapy can improve the 3.5-year distant metastasis-free survival in patients with resected high-risk stage III cutaneous melanoma, with a more significant effect in patients with PD-L1-positive tumors.

LANCET ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly et al.

Summary: In patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, adjuvant therapy with nivolumab significantly improved disease-free survival compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials

Francesco Massari et al.

Summary: This study conducted a meta-analysis on the latest clinical trial data of immune-based combinations in mRCC, demonstrating the significant advantages of immune-based combinations in reducing the risk of death and extending PFS, as well as improving CR rate and ORR.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study showed that adjuvant pembrolizumab therapy significantly improved disease-free survival compared to placebo among high-risk kidney cancer patients after surgery, with a positive impact on overall survival as well.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

D. F. Bajorin et al.

Summary: In a trial involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, adjuvant nivolumab showed longer disease-free survival compared to placebo, especially among patients with a PD-L1 expression level of 1% or more, despite an increase in treatment-related adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Lisa Zimmer et al.

LANCET (2020)

Add to Collection

Article Oncology

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Thomas Powles et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Cancer and the Immune System: The History and Background of Immunotherapy

Maura Abbott et al.

SEMINARS IN ONCOLOGY NURSING (2019)

Add to Collection

Article Oncology

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Martin Reck et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Review Oncology

Cancer immunoediting and resistance to T cell-based immunotherapy

Jake S. O'Donnell et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Cancer immunotherapy: broadening the scope of targetable tumours

Jitske van den Bulk et al.

OPEN BIOLOGY (2018)

Add to Collection

Review Immunology

Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant

Willem W. Overwijk

CURRENT OPINION IN IMMUNOLOGY (2017)

Add to Collection

Editorial Material Medicine, Research & Experimental

Cancer immunotherapy: harnessing the immune system to battle cancer

Yiping Yang

JOURNAL OF CLINICAL INVESTIGATION (2015)

Add to Collection

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

Add to Collection

Review Medicine, General & Internal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

PLOS MEDICINE (2009)

Add to Collection

Article Medicine, General & Internal

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

David Moher et al.

BMJ-BRITISH MEDICAL JOURNAL (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.